Oct 1, 2026 · 1h 4m
Personalized medicine collides with insurance and evidence gaps
The Testosterone, Weight Loss & Hormone Lies Your Doctor Never Told You | Brigham Buhler
The conversation examines how financial incentives and regulatory limits shape access to emerging treatments while questioning how clinicians should weigh evidence against individual experience.
- 1Insurance and pharmacy benefit structures can steer preventive care and GLP-1 treatment toward standardized, higher-cost pathways.
- 2Buhler and Axe argue that genetic, metabolic, and symptom data can support more individualized dosing and supplementation.
- 3The episode acknowledges peptide hype and evidence limitations while defending cautious experimentation alongside nutrition, training, and clinical judgment.
Don't miss
The most revealing exchange contrasts the minimum effective GLP-1 dose with insurance and pharmacy-benefit incentives that can push treatment toward higher doses and costs.
The brief
Brigham Buhler and Josh Axe frame modern medicine around a central tension: conventional systems excel at acute care but often leave preventive and individualized treatment underserved.
They trace that gap to insurance exclusions, pharmacy benefit managers, and regulatory costs, arguing that financial structures can influence which tests, doses, and therapies patients receive.
The discussion moves through genetic testing, methylated B vitamins, NAD-related supplements, GLP-1 dosing, and the principle of introducing interventions one at a time at the minimum effective dose.
Peptide therapy becomes the test case: the hosts criticize exaggerated claims and acknowledge limited evidence, while arguing that patient experience and careful clinical judgment still matter.
The episode closes by calling for medicine that observes individual biology more closely, without abandoning nutrition, lifestyle, formal research, or skepticism about emerging treatments.